HC Wainwright Issues Positive Forecast for enGene Earnings

enGene Holdings Inc. (NASDAQ:ENGN - Free Report) - Equities researchers at HC Wainwright increased their Q3 2025 earnings estimates for enGene in a research note issued to investors on Monday, June 16th. HC Wainwright analyst A. Maldonado now expects that the company will earn ($0.52) per share for the quarter, up from their previous estimate of ($0.63). HC Wainwright currently has a "Buy" rating and a $25.00 price target on the stock. The consensus estimate for enGene's current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for enGene's Q4 2025 earnings at ($0.54) EPS, FY2026 earnings at ($2.09) EPS, FY2027 earnings at ($1.87) EPS, FY2028 earnings at ($0.92) EPS and FY2029 earnings at ($0.14) EPS.

enGene (NASDAQ:ENGN - Get Free Report) last issued its quarterly earnings results on Tuesday, June 10th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.03).

A number of other research analysts have also recently commented on ENGN. Morgan Stanley reduced their target price on enGene from $37.00 to $34.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 11th. JMP Securities reiterated a "market outperform" rating and set a $18.00 price objective on shares of enGene in a research report on Tuesday, April 29th. Finally, Piper Sandler started coverage on shares of enGene in a research report on Tuesday, February 18th. They set an "overweight" rating and a $26.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, enGene currently has a consensus rating of "Buy" and an average price target of $23.29.

enGene Price Performance

Shares of NASDAQ:ENGN opened at $3.25 on Wednesday. The firm has a market capitalization of $165.69 million, a price-to-earnings ratio of -1.97 and a beta of -0.40. The company has a debt-to-equity ratio of 0.09, a current ratio of 12.66 and a quick ratio of 12.66. enGene has a one year low of $2.65 and a one year high of $11.00. The company's fifty day moving average price is $3.75 and its 200-day moving average price is $5.40.

Hedge Funds Weigh In On enGene

Several institutional investors and hedge funds have recently bought and sold shares of ENGN. Vontobel Holding Ltd. bought a new position in enGene during the 4th quarter worth approximately $69,000. Blue Owl Capital Holdings LP grew its holdings in shares of enGene by 3.3% in the fourth quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company's stock worth $21,014,000 after purchasing an additional 101,006 shares during the last quarter. Jane Street Group LLC bought a new position in shares of enGene in the fourth quarter worth approximately $93,000. Cubist Systematic Strategies LLC grew its holdings in shares of enGene by 15.7% in the fourth quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company's stock worth $102,000 after purchasing an additional 2,080 shares during the last quarter. Finally, Corton Capital Inc. bought a new position in shares of enGene in the fourth quarter worth approximately $157,000. 64.16% of the stock is currently owned by institutional investors.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.